TARA

$2.41+0.00%visit website

Protara Therapeutics, Inc.

Market Cap

$142M

Live price × SEC shares (Aug 7, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.53

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

0.9

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	9,591	13,124	13,562	16,955	53,232
Total operating expenses	14,760	19,079	19,629	23,324	76,792
Operating income	(14,760)	(19,079)	(19,629)	(23,324)	(76,792)
Net income	(13,258)	(17,307)	(17,782)	(21,668)	(70,015)
EPS (basic) ($)	(0.31)		(0.31)	(0.36)	—
EPS (diluted) ($)	(0.31)		(0.31)	(0.36)	—
Weighted avg. shares (basic)	42,272		57,539	61,007
Weighted avg. shares (diluted)	42,272		57,539	61,007

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 11, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 50 more quarters, back to Mar 2013, with Tormere Pro.

Corporate Events (8-K)

12 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 11, 2026 accepted 8:05 AM ET	2.02Earnings release	Document SEC ↗
Jun 29, 2026 accepted 5:02 PM ET	5.02Officer / director change	Document SEC ↗
Jun 15, 2026 accepted 4:05 PM ET	5.07Shareholder vote	Document SEC ↗
May 13, 2026 accepted 8:05 AM ET	2.02Earnings release	Document SEC ↗
Mar 30, 2026 accepted 8:00 AM ET	7.01Reg FD disclosure	Document SEC ↗
Mar 10, 2026 accepted 8:06 AM ET	2.02Earnings release	Document SEC ↗
Feb 24, 2026 accepted 8:52 AM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗
Dec 15, 2025 accepted 4:15 PM ET	8.01Other events	Document SEC ↗
Dec 8, 2025 accepted 4:15 PM ET	1.01Material agreement	Document SEC ↗
Dec 3, 2025 accepted 8:08 AM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

34%

W/W +26.7pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-06-29	2026-07-01	Shefferman Jesse	Director & CEO and President	Sale	215.7K	$4.09	$882K	721.8K	View
2026-04-08	2026-04-09	Zummo Jacqueline	Chief R&D Officer	Sale	1,134	$5.40	$6K	94.8K	View
2026-04-01	2026-04-02	Zummo Jacqueline	Chief R&D Officer	Sale	22.6K	$5.26	$119K	96.0K	View